Altamira Therapeutics Ltd (CYTO)

Feb 15, 2025

Auris Medical and King's College London Extend Tinnitus Collaboration -February 22, 2017 at 08:02 am EST - Marketscreener.com

Feb 15, 2025

Jan 27, 2025

Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19 - ACCESS Newswire

Jan 27, 2025

Jan 25, 2025

Altamira Therapeutics and Avernus Pharma Collaborate for Marketing and Distribution of Bentrio in Gulf Countries - ACCESS Newswire

Jan 25, 2025

Jan 22, 2025

Altamira Therapeutics Ltd. Announces Collaboration on Radiopharmaceutical Targeting Strategies - Marketscreener.com

Jan 22, 2025

Jan 22, 2025

Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies - GlobeNewswire

Jan 22, 2025

Jan 02, 2025

Altamira Therapeutics achieves nanoparticle-based delivery of circular mRNA - BioWorld Online

Jan 02, 2025

Dec 31, 2024

Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA - The Manila Times

Dec 31, 2024

Dec 30, 2024

Altamira Therapeutics Ltd. Announces Successful Nanoparticle-Based Delivery of Circular RNA - Marketscreener.com

Dec 30, 2024

Dec 26, 2024

Nasdaq de-lists Altamira shares - Royal Gazette

Dec 26, 2024

Dec 23, 2024

Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets - Marketscreener.com

Dec 23, 2024

Dec 20, 2024

Altamira Therapeutics Moves to OTCQB After Nasdaq Delisting Over Minimum Bid Requirements - StockTitan

Dec 20, 2024

Dec 19, 2024

Altamira Therapeutics (NASDAQ:CYTO) Stock Price Down 1.3% – Here’s What Happened - Defense World

Dec 19, 2024

Dec 11, 2024

Loud and clear: Sound Pharma has phase III success in Meniere’s - BioWorld Online

Dec 11, 2024

Nov 28, 2024

CYTO stock plunges to 52-week low, touches $0.4 By Investing.com - Investing.com South Africa

Nov 28, 2024

Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in Altamira Therapeuti - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews

Nov 14, 2024

Oct 22, 2024

CYTO stock plunges to 52-week low, hitting $0.57 amid market challenges - Investing.com Australia

Oct 22, 2024

Oct 15, 2024

Here's Why Auris (CYTO) Is a Great 'Buy the Bottom' Stock Now - Nasdaq

Oct 15, 2024

Oct 11, 2024

Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets - AsiaOne

Oct 11, 2024

Oct 05, 2024

Altamira Therapeutics faces Nasdaq delisting over share price - Investing.com India

Oct 05, 2024

Oct 05, 2024

Altamira Therapeutics Provides Update on Nasdaq Listing - The Manila Times

Oct 05, 2024

Oct 04, 2024

Altamira Therapeutics Faces Nasdaq Delisting - TipRanks

Oct 04, 2024

Oct 04, 2024

Altamira Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com UK

Oct 04, 2024

Sep 30, 2024

CYTO stock plunges to 52-week low, touches $0.65 By Investing.com - Investing.com South Africa

Sep 30, 2024

Sep 30, 2024

CYTO stock plunges to 52-week low, touches $0.65 - Investing.com India

Sep 30, 2024

Sep 28, 2024

Altamira Medica obtains extended ISO 13485 certification By Investing.com - Investing.com South Africa

Sep 28, 2024

Sep 27, 2024

Altamira Medica obtains extended ISO 13485 certification - Investing.com

Sep 27, 2024

Sep 27, 2024

Altamira Therapeutics Announces Extended ISO 13485 Quality - GlobeNewswire

Sep 27, 2024

Sep 27, 2024

Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray - StockTitan

Sep 27, 2024

Sep 25, 2024

Earnings call: Altamira Therapeutics focuses on RNA delivery growth By Investing.com - Investing.com Australia

Sep 25, 2024

Sep 25, 2024

Earnings call: Altamira Therapeutics focuses on RNA delivery growth - Investing.com

Sep 25, 2024

Sep 25, 2024

Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2024 Earnings Call Transcript - Insider Monkey

Sep 25, 2024

Sep 25, 2024

Altamira Therapeutics Ltd (CYTO) Q2 2024 Earnings Call Transcript Highlights: Key Financial and ... By GuruFocus - Investing.com Canada

Sep 25, 2024

Sep 24, 2024

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - GlobeNewswire

Sep 24, 2024

Sep 23, 2024

Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics - Digital More

Sep 23, 2024

Sep 23, 2024

Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia - The Manila Times

Sep 23, 2024

Sep 20, 2024

Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 - GlobeNewswire

Sep 20, 2024

Sep 19, 2024

Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering - GlobeNewswire

Sep 19, 2024

Sep 19, 2024

Altamira Issues Pre-Funded Share Purchase Warrant - TipRanks

Sep 19, 2024

Sep 17, 2024

Altamira Therapeutics announces $4 million public offering - Investing.com India

Sep 17, 2024

Sep 17, 2024

Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering - The Bakersfield Californian

Sep 17, 2024

Sep 16, 2024

Altamira Therapeutics Announces Expansion of Bentrio - GlobeNewswire

Sep 16, 2024

Sep 16, 2024

Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with - The Bakersfield Californian

Sep 16, 2024